Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/28/2024 | $34.00 | Equal Weight | Wells Fargo |
| 7/10/2024 | $43.00 | Buy | Craig Hallum |
| 6/3/2024 | $21.00 | Hold | Jefferies |
Veteran Legal Executive from Zoetis and Pfizer Joins GeneDx Executive Leadership Team to Lead Legal, Compliance and Policy Functions GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Heidi Chen as Chief Legal Officer, effective November 25, 2024. In her role, Heidi will report to Katherine Stueland, CEO and President, and will serve on the executive leadership team. With over 30 years of experience, Heidi will lead all legal, compliance, and policy functions at GeneDx and will provide strategic counsel on corporate governance, intellectual property, regulatory matters, federal policy, compliance and more.
Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4
Anagenex, a pioneering drug discovery company pairing large-scale data generation with proprietary artificial intelligence (AI) to discover the next generation of small molecule medicines, today announced the appointment of Robert Forrester as Executive Chairman of its Board of Directors. The company also welcomed Isaac Ro to its Board of Directors. "Robert and Isaac's extensive experience as life science executives is invaluable to the Anagenex team as we realize our vision of becoming a vertically integrated small molecule drug discovery company," said Nicolas Tilmans, CEO of Anagenex. "Our unique AI driven platform has already powered two lead programs with novel chemical matter and co
Wells Fargo initiated coverage of GeneDx with a rating of Equal Weight and set a new price target of $34.00
Craig Hallum initiated coverage of GeneDx with a rating of Buy and set a new price target of $43.00
Jefferies resumed coverage of GeneDx with a rating of Hold and set a new price target of $21.00
4/A - GeneDx Holdings Corp. (0001818331) (Issuer)
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
144 - GeneDx Holdings Corp. (0001818331) (Subject)
144 - GeneDx Holdings Corp. (0001818331) (Subject)
144 - GeneDx Holdings Corp. (0001818331) (Subject)
New Biopharma Solution Aims to Accelerate the Delivery of Precision Medicine to More Patients GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced GeneDx Discover, a first-of-its-kind data visualization tool, which provides biopharmaceutical companies access to deidentified and aggregated genetic data - powered by GeneDx's robust database - to improve all stages of drug development. The new offering is part of GeneDx's ongoing investment to deliver personalized and actionable health insights to inform diagnosis, direct treatment, and improve drug discovery. Today's drug discovery and development process is not scalable to meet so
Veteran Legal Executive from Zoetis and Pfizer Joins GeneDx Executive Leadership Team to Lead Legal, Compliance and Policy Functions GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Heidi Chen as Chief Legal Officer, effective November 25, 2024. In her role, Heidi will report to Katherine Stueland, CEO and President, and will serve on the executive leadership team. With over 30 years of experience, Heidi will lead all legal, compliance, and policy functions at GeneDx and will provide strategic counsel on corporate governance, intellectual property, regulatory matters, federal policy, compliance and more.
Data demonstrates the strength of GeneDx's diverse database; exome diagnostic rate is high regardless of patient's ancestral background GeneDx industry leading dataset from 46% non-white populations GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced the results of an extensive study shedding light on the critical issue of racial disparities in access to an accurate genetic diagnosis. The study, a collaboration among GeneDx, The University of Washington, Brotman Baty Institute for Precision Medicine, Geisinger and Seattle Children's Hospital, was conducted on nearly 187,000 samples performed and across approximately 73,000 patient
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)
SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)
SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)
Achieved profitability milestone with third quarter adjusted net income1 of $1.2M Reported third quarter 2024 revenues2 of $76.6M with 77% year-over-year growth of exome and genome test revenue Expanded third quarter 2024 adjusted gross margins2 to 64% Raising guidance to deliver between $284M and $290M in FY 2024 revenue GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the third quarter of 2024. "We delivered 77% growth on exome and genome revenues in Q3 and have reached the point of profitability, a significant milestone in our co
GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the third quarter of 2024 before the market opens on Tuesday, October 29, 2024. Management will host a conference call that day to discuss third quarter 2024 financial and operating results at 8:30 a.m. Eastern Time. Conference Call Details Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the GeneDx investor relations website at https://ir.genedx.com/. About GeneDx At GeneDx (NASDAQ:WGS), we believe that everyone de
Reported second quarter 2024 revenue from continuing operations1 of $68.9M with 77% year-over-year growth of exome and genome test revenue Expanded second quarter 2024 adjusted gross margins2 from continuing operations to 62% Narrowed second quarter 2024 adjusted net loss2 to $2.7M Raising guidance to deliver between $255M and $265M in FY 2024 revenue and reiterate path to profitability in 2025 GeneDx to host conference call today at 4:30 p.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the second quarter of 2024. "Our continued organizational focus on execution fueled o
GeneDx Holdings Corp. (NASDAQ:WGS) has made the biggest gains on the Russell 2000 Index in 2024 as the biotechnology company moves toward more comprehensive genetic testing. The Maryland-based company’s shares have soared 1,101% so far this year as of midday Thursday, according to Tradingview. Goldman Sachs analyst Matthew Sykes attributes much of GeneDX’s positive momentum to shifting its testing. The company went from panel-based tests, which look for variants in more than one gene, to exome/genome testing, which analyzes the bulk of a person’s DNA to find genetic variations. Also Read: GeneDx Stock Climbs After Better-Than-Expected Q1 Results, Raises FY24 Guidance “We remain o
In the preceding three months, 6 analysts have released ratings for GeneDx Hldgs (NASDAQ:WGS), presenting a wide array of perspectives from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 0 1 0 0 Last 30D 0 0 1 0 0 1M Ago 2 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 3 0 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $27.33, with a high estimate of $43.00 and a low estimate of $15.00. Observing a 91.12% increa
Goldman Sachs analyst Matthew Sykes maintains GeneDx Hldgs (NASDAQ:WGS) with a Neutral and raises the price target from $12.5 to $28.